Drug Trial Radar · NCT04023526
A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
103
Actual
Start
Jul 29, 2019
Primary completion
Aug 15, 2023
Study completion May 15, 2027
Sponsor
- Lead sponsor
- OncoVerity, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- argenx; Janssen Research & Development, LLC
- First posted
- Jul 17, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy of cusatuzumab in combination with azacitidine in participants with previously untreated acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy.
Conditions
- Leukemia, Myeloid, Acute
Interventions
AzacitidineDrug
Azacitidine SC or IV will be administered at a standard dose of 75 mg/m\^2 on days 1-7 of each cycle.
CusatuzumabDrug
Cusatuzumab IV will be administered as 10 mg/kg or 20 mg/kg on days 3 and 17 of each cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Complete Remission (CR)Time frame: Up to 3 years and 5 months
Locations
56 sites in 9 countries. Site status is shown where the registry gives one.
St Vincents Hospital Sydney
Darlinghurst, Australia
St Vincents Hospital Melbourne
Fitzroy, Australia
The Alfred Hospital
Melbourne, Australia
Royal Perth Hospital
Perth, Australia
Westmead Hospital
Westmead, Australia
Universidade Estadual De Campinas
Campinas, Brazil
Hospital das Clinicas de Porto Alegre
Porto Alegre, Brazil
CHU d'Angers
Angers, France
CHU Grenoble
Grenoble, France
Institut Paoli Calmettes
Marseille, France
Centre Hospitalier Universitaire (CHU) de Bordeaux Hopital HautLeveque Centre Francois Magendie
Pessac, France
CHU Lyon Sud
Pierre-Bénite, France
Institut Universitaire du Cancer Toulouse Oncopole
Toulouse, France
CHRU Tours Hôpital Bretonneau
Tours, France
Rambam Medical Center
Haifa, Israel
Hadassah Medical Center
Jerusalem, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Azienda Opedaliero-Universitaria Policlinico Sant'orsola Malpighi di Bologna
Bologna, Italy
Azienda Ospedaliera Spedali Civili di Brescia
Brescia, Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, Italy
Istituto Europeo di Oncologia
Milan, Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy
Division of Hematology, Cardarelli Hospital
Naples, Italy
Azienda Sanitaria Universitaria Integrata di Udine
Udine, Italy
Chelyabinck Regional Clinical Hospital
Chelyabinsk, Russia
S.P. Botkin Moscow City Clinical Hospital
Moscow, Russia
City Clinical Hospital # 40
Moscow, Russia
Nizhniy Novgorod Region Clinical Hospital
Nizhny Novgorod, Russia
Ryazan Regional Clinical Hospital
Ryazan, Russia
St.-Petersburg Clinical Research Institute of Hematology and Transfusiology
Saint Petersburg, Russia
City clinical hospital #15
Saint Petersburg, Russia
Samara Region Clinical Hospital
Samara, Russia
Oncologic Dispensary No.2
Sochi, Russia
Komi Republic Oncology dispensary
Syktyvkar, Russia
Ekaterinburg City Clinical Hospital # 7
Yekaterinburg, Russia
Hosp. de La Santa Creu I Sant Pau
Barcelona, Spain
Inst. Cat. Doncologia-H Duran I Reynals
Barcelona, Spain
Hosp. Univ. Vall D Hebron
Barcelona, Spain
Hosp. Reina Sofia
Córdoba, Spain
Hosp. Univ. Ramon Y Cajal
Madrid, Spain
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.